Seoul, South Korea

Man Dong Rho

This inventor holds 2 USPTO granted patents and 2 EPO patents. Top assignees: Dong Kook Pharm Co., Ltd, Dongkook Pharmaceutical Co., Ltd.. Active years: 2013-2014.


% Patents Active = 50.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Man Dong Rho: Innovator in Pharmaceutical Chemistry

Introduction

Man Dong Rho is a notable inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds and methods for drug preparation. With a total of 2 patents, Rho's work has had a meaningful impact on the industry.

Latest Patents

Rho's latest patents include the "Montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same." This patent discloses a novel montelukast 4-halobenzylamine salt and a method for preparing a montelukast sodium salt in a single reactor without additional processes. The second patent, "Process for preparing voriconazole by using new intermediates," outlines a method for synthesizing Voriconazole with high optical purity and cost-efficiency through a series of chemical reactions.

Career Highlights

Throughout his career, Rho has worked with prominent companies such as Dong Kook Pharm Co., Ltd and Dongkook Pharmaceutical Co., Ltd. His expertise in pharmaceutical development has positioned him as a valuable asset in the industry.

Collaborations

Rho has collaborated with notable professionals in his field, including Hyuk Chul Kwon and Kyung Hoi Cha. These collaborations have further enhanced his research and development efforts.

Conclusion

Man Dong Rho's innovative work in pharmaceutical chemistry, particularly through his recent patents, showcases his commitment to advancing drug development. His contributions continue to influence the industry positively.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…